Literature DB >> 6594492

Single-dose pharmacokinetics of imipenem in children.

R F Jacobs, G L Kearns, J M Trang, A L Brown, B Marmer, J C McIntosh, F L Underwood, R B Kluza.   

Abstract

The single-dose pharmacokinetics of imipenem (N-formimidoyl thienamycin) was evaluated in 13 pediatric patients (mean age 5.2 +/- 3.5 years). Imipenem was administered in combination with cilastatin as either a 10 mg/kg or 25 mg/kg dose (not to exceed 500 mg) over 15 minutes. Plasma disposition in children was best described by a two-compartment open model. The distribution phase was rapid (t1/2 lambda 1 = 0.18 hours) and was followed by a monoexponential elimination phase (t1/2 lambda 2 = 1.2 hours). The calculated value for the apparent volume of distribution (0.66 L/kg) was similar to that of total body water. The total plasma clearance was rapid (0.36 L/hr/kg). Direct proportionality was exhibited between administered dose and either resultant plasma concentration or area under the plasma concentration versus time curve. Comparison of imipenem plasma pharmacokinetic data derived from these children with data reported from adult subjects revealed disparities for both the apparent volume of distribution and plasma clearance. Based on preliminary pharmacokinetic simulations using parameters generated from our study, a 25.0 mg/kg dose of imipenem administered every 6 hours appears adequate for initiation of therapy in children.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594492     DOI: 10.1016/s0022-3476(84)80098-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  12 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.

Authors:  Lei Dong; Xiao-Ying Zhai; Yi-Lei Yang; Li Wang; Yue Zhou; Hai-Yan Shi; Bo-Hao Tang; Yue-E Wu; Fan Yang; Li Wen; Hong-Xiao Kong; Li-Juan Zhi; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Prospective determination of plasma imipenem concentrations in critically ill children.

Authors:  Eric Giannoni; Philippe Moreillon; Jacques Cotting; Adrien Moessinger; Jacques Bille; Laurent Décosterd; Giorgio Zanetti; Paul Majcherczyk; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life.

Authors:  M D Reed; R M Kliegman; T S Yamashita; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 5.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 6.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

Review 7.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

Review 8.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.

Authors:  Samir G Sakka; Anna K Glauner; Jürgen B Bulitta; Martina Kinzig-Schippers; Wolfgang Pfister; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

10.  Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections.

Authors:  R F Jacobs; G L Kearns; A L Brown; D C Longee
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.